Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

METHODS OF DIAGNOSING A DISEASE AND METHODS OF MONITORING TREATMENT OF A DISEASE BY QUANTIFYING A NON-REDUCING END GLYCAN RESIDUAL COMPOUND AND COMPARING TO A SECOND BIOMARKER

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Detection of oligosaccharides

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 2. The process of claim 1 , wherein the process is a process for diagnosing the presence claim 1 , identity claim 1 , and/or severity of an abnormal glycosaminoglycan accumulation disorder claim 1 , which is an MPS disorder.3. The process of claim 1 , wherein the saturated oligosaccharide biomarker is generated by treating a population of heparan sulfate oligosaccharides with at least one heparan sulfate digesting lyases.4. (canceled)5. The process of claim 1 , wherein the saturated oligosaccharide biomarker is generated by treating a population of chondroitin sulfate oligosaccharides with at least one chondroitin sulfate digesting lyase.6. The process of claim 1 , wherein the saturated oligosaccharide biomarker is generated by treating a population of dermatan sulfate oligosaccharides with at least one dermatan sulfate digesting lyase.7. The process of claim 1 , wherein the process of preparing the transformed biological sample further comprises purifying a population of oligosaccharides in the biological sample that has been treated with the at least one digesting glycosaminoglycan lyase claim 1 , the transformed biological sample comprising the isolated population of oligosaccharides.8. The process of claim 1 , wherein the transformed biological sample has been purified using chromatography or electrophoresis.9. (canceled)10. (canceled)11. The process of claim 1 , wherein the process of preparing the transformed biological sample further comprises tagging the reducing end or non-reducing end of a representative portion of the one or more oligosaccharides in the transformed biological sample with a detectable label.12. The process of claim 11 , wherein the detectable label is a mass label claim 11 , a radio label claim 11 , ...

N-linked glycan biosynthesis modulators

Provided herein are N-linked glycan inhibitors, including modulators of N-linked glycan glycosylation, mannosidase, an N-linked glycan N-acetylglucosaminyl transferase, an N-linked glycan fucosyl transferase, an N-linked glycan galactosyl transferase, an N-linked glycan sialyl transferase, an N-linked glycan sulfotransferase, N-linked glycan glycophosphotransferase or a combination thereof.

GLYCOSAMINOGLYCAN INHIBITORS

Provided herein are chondroitin sulfate inhibitors, including modulators of glycosylation, and/or sulfation of galactose or N-acetyl galactosamine glycosaminoglycans. 1. A process for modifying the structure of chondroitin sulfate on a core protein , comprising contacting a cell that translationally produces at least one core protein having at least one attached chondroitin sulfate moiety with a selective inhibitor of a chondroitin sulfate glycosyltransferase , a chondroitin sulfate sulfotransferase , or a chondroitin sulfate phosphotransferase.2. The process of claim 1 , wherein the selective inhibitor of a chondroitin sulfate sulfotransferase is an inhibitor of a chondroitin sulfate O-sulfotransferase.3. The process of claim 2 , wherein the inhibitor of a chondroitin sulfate O-sulfotransferase inhibits the 6-OH sulfation of a galactosaminyl moiety claim 2 , the 4-OH sulfation of a galactosaminyl moiety claim 2 , the 2-OH sulfation of a uronic acid moiety claim 2 , or a combination thereof.4. The process of claim 1 , wherein the inhibitor of a chondroitin sulfate glycosyltransferase inhibits the synthesis of the linkage region claim 1 , the modification of the linkage region claim 1 , the initiation of chondroitin sulfate synthesis claim 1 , the synthesis of chondroitin sulfate claim 1 , or a combination thereof.5. A process of inhibiting chondroitin sulfate function in a cell comprising contacting the cell with a selective modulator of a chondroitin sulfate glycosyltransferase or a modulator of a chondroitin sulfate sulfotransferase.6. The process of claim 5 , wherein the chondroitin sulfate function inhibited is an ability to bind a chondroitin sulfate binding lectin.7. The process of claim 6 , wherein the chondroitin sulfate lectin is a growth factor.8Plasmodium falciparum. The process of claim 7 , wherein the growth factor is a fibroblast growth factor (FGF) claim 7 , heparin binding epidermal growth factor (HB-EGF) claim 7 , vascular endothelial growth factor ...

QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation. 1. A method of diagnosing an individual as having a disease or condition associated with abnormal glycan biosynthesis , degradation , or accumulation , the method comprising:(a) generating a biomarker comprising of one or more non-reducing end glycan residual compound, wherein the biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzymes, wherein prior to enzyme treatment, the biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition, and 'wherein the presence of and/or measure the amount of the biomarker is utilized to determine the presence, identity, and/or severity of the disease or condition; and', '(b) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or a measure of a population of the biomarker;'}wherein the disease or condition is a lysosomal storage disorder or a neurological disorder; andwherein when the lysosomal storage disorder is an MPS disorder, then the digesting glycan enzyme is not a lyase.2. The method of claim 1 , wherein the disease or disorder is caused by an abnormally functioning glycan degradation enzyme and wherein the abnormally functioning glycan degradation enzyme and the normally functioning glycan degradation enzyme are of the same type.3. (canceled)4. (canceled)5. The method of claim 1 , wherein the abnormal glycan accumulation comprises the accumulation of abnormal amounts of normal glycans.6. The method of claim 1 , wherein the abnormal glycan accumulation comprises the accumulation of abnormal amounts of abnormal glycans.7. The method of claim 1 , wherein the normally ...

QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation. 1. A method of diagnosing an individual as having a disease or condition associated with abnormal glycan biosynthesis , degradation , or accumulation , the method comprising:(a) generating a first biomarker comprising a glycan residual compound, wherein the first biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme, wherein prior to enzyme treatment, the first biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition,(b) generating a second biomarker comprising a glycan residual compound, wherein the second biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme in the same or different digestion step as provided in step (a), wherein prior to enzyme treatment, the second biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition,(c) using an analytical instrument to detect the presence of and/or measure the amount of the first and second biomarker produced and displaying or recording the presence of or a measure of a population of the first and second biomarkers, and(d) monitoring and/or comparing the amounts of the first and second biomarkers in a biological sample;wherein the presence of and/or measure of the amounts of the first and second biomarkers are utilized to determine the presence, identity, and/or severity of the disease or condition.2. The method of claim 1 , wherein the first biomarker is a non-reducing end glycan residual compound.3. The method of claim 1 , wherein the disease or disorder is ...

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130-. (canceled)31. A method of determining in an individual the presence , identity , and/or severity of an MPS IIIA or MPS IIIB disorder , the method comprising:(a) generating a biomarker comprising one or more saturated non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of heparan sulfate oligosaccharides, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS IIIA or MPS IIIB disorder relative to individuals without the MPS IIIA or MPS IIIB disorder; and(b) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence of and/or measure of the amounts of the biomarker are utilized to determine the presence, identity, and/or severity of the MPS III disorder; andwherein the biomarker is selected from a group consisting of{'sub': '3', 'Formula III: [GlcNS-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula IV: [GlcNS-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula V: [GlcNAc-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula VI: [GlcNAc-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula VIII: [GlcN-GlcA-GlcN(Ac)0-1](SOR)0-4;'}{'sub': '3', 'Formula IX: [GlcNAc6S-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula X: [GlcNAc6S-GlcA-GlcN(Ac)0-1](SOR)0-2;'}GlcN-IdoA-GlcNAc;GlcN-IdoA2S-GlcNAc;GlcN-IdoA-GlcNS;GlcN-IdoA-GlcNAc6S;GlcN-IdoA2-GlcNAc6S; andGlcN-IdoA-GlcNS6S.32. The method of claim 31 , wherein the biomarker is of Formula V: [GlcNAc-IdoA-GlcN(Ac)-1](SOR); or ...

METHODS OF DIAGNOSING A DISEASE AND METHODS OF MONITORING TREATMENT OF A DISEASE BY QUANTIFYING A NON-REDUCING END GLYCAN RESIDUAL COMPOUND AND COMPARING TO A SECOND BIOMARKER

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation. 126.-. (canceled)27. A method of determining in an individual the presence , identity , and/or severity of mucopolysaccharidosis (MPS) III , the method comprising: 'wherein prior to enzyme treatment, the first biomarker is not present in abundance in samples from individuals with MPS III relative to individuals without MPS III, and wherein the first biomarker is a non-reducing end (NRE) biomarker;', '(a) generating a first biomarker comprising a glycan residual compound, wherein the first biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme,'} wherein prior to enzyme treatment, the second biomarker is not present in abundance in samples from individuals with the MPS III relative to individuals without the MPS III, and wherein:', '1) the second biomarker is a reducing end biomarker,', '2) the second biomarker is an internal glycan biomarker, or', '3) when the MPS III is caused by an abnormal function of a glycan degradation enzyme in the individual, the second biomarker is generated by treating the first biomarker with the glycan degradation enzyme that is functioning abnormally in the individual;, '(b) generating a second biomarker comprising a glycan residual compound, wherein the second biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme,'}(c) detecting the presence of and/or measuring the amount of the first and second biomarker produced and displaying or recording the presence of or a measure of a population of the first and second biomarkers by using an analytical instrument; and(d) monitoring and/or comparing the amounts of the first and second biomarkers in a biological sample; ...

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130.-. (canceled)31. A method for determining in an individual , the presence , identity , and/or severity of MPS I disorder , the method comprising:a) generating a biomarker comprising of one or more non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of glycosaminoglycans, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS I disorder relative to individuals without the MPS I disorder; andb) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence and/or the measure of the amount of the biomarker are utilized to determine the presence, identity, and/or severity of MPS I disorder; andwherein the biomarker is selected from a group consisting ofFormula I-A: IdoA-GlcNAc;Formula I-B: IdoA-GlcNS;Formula I-C: IdoA-GlcNS6S;{'sub': 3', 'n, 'Formula XII: [IdoA-GalNAc](SOR), wherein n is 0-2;'}{'sub': 3', 'n, 'Formula XXI: [IdoA-GlcN(Ac)m-IdoA](SOR), where m is 0-1 and n is 0-4;'}{'sub': 3', 'n, 'Formula XXII: [IdoA-GlcN(Ac)m-GlcA](SOR), where m is 0-1 and n is 0-3; and'}{'sub': 3', 'n, 'Formula XXIII: [GlcA-GlcN(Ac)m-GlcA](SOR), where m is 0-1 and n is 0-3.'}32. The method of claim 31 , wherein the biomarker is selected from the group consisting of: Formula I-A: IdoA-GlcNAc; Formula I-B: IdoA-GlcNS; Formula I-C: IdoA-GlcNS6S; and Formula XII: [IdoA-GalNAc](SO3R)n claim 31 , wherein n is 0-2.33. The method of claim 31 , wherein the biomarker is selected from the ...

QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS FOR DETERMINGING THE PRESENCE, IDENTITY, OR SEVERITY OF A DISEASE OR CONDITION

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation. 128.-. (canceled)29. A method of determining the presence , identity , and/or severity of a disease or condition in an individual , where the disease or condition is associated with abnormal glycan biosynthesis , degradation , or accumulation , the method comprising:(a) generating a biomarker comprising of one or more non-reducing end glycan residual compound(s), wherein the biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme(s), wherein prior to enzyme treatment, the biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition;(b) detecting the presence of and/or measuring the amount of the biomarker produced using an analytical instrument and displaying or recording the presence of or the measure of the biomarker produced; and(c) correlating the presence of and/or the measure of the amount of the biomarker with the presence, identity, and/or severity of the disease or condition for determining the presence, identity, and/or severity of the disease or condition,wherein the digesting glycan enzyme(s) are selected from the group consisting of glycosidases, sulfatases, phosphorylases, deacetylases, and sialidases, or combinations thereof.30. The method of claim 29 , wherein the digesting glycan enzyme(s) is a glycosidase or a combination of glycosidases.31. The method of claim 30 , wherein the glycosidase is an exo-glycosidase or a combination of exo-glycosidases.32. The method of claim 31 , wherein the exo-glycosidase is a galactosidase claim 31 , a glucuronidase claim 31 , or a combination thereof.33. The method of claim 30 , wherein the glycosidase is a glycosidase claim 30 , an N-acetyl glycosidase claim ...

Quantification of Non-Reducing End Glycan Residual Compounds

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation. 1. A method of diagnosing an individual as having a disease or condition associated with abnormal glycan biosynthesis , degradation , or accumulation , the method comprising:(a) generating a biomarker comprising of one or more non-reducing end glycan residual compound(s), wherein the biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme(s), wherein prior to enzyme treatment, the biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition, and(b) using an analytical instrument to detect the presence of and/or to measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;(c) determining the presence, identity, and/or severity of the disease or condition utilizing the presence of and/or the measure of the amount of the biomarker;wherein the disease or condition is a lysosomal storage disease, cancer, an inflammatory disease, a liver disease, a bone disease, an infectious disease, a central nervous system disease, or a cardiovascular disease; andwherein when the lysosomal storage disease is an MPS disorder and when the disease or condition is osteoarthritis, then the digesting glycan enzyme is not a lyase.2. The method of claim 1 , wherein the disease or condition is caused by an abnormally functioning glycan degradation enzyme and wherein the abnormally functioning glycan degradation enzyme and one of the digesting glycan enzymes are of the same type.36-. (canceled)7. The method of claim 1 , wherein at least one of the digesting glycan enzymes is selected from a sialidase claim 1 , hexosaminidase claim 1 , fucosidase claim 1 , N-acetyl- ...

QUANTIFICATION OF NON-REDUCING END GLYCAN RESIDUAL COMPOUNDS FOR DETERMINING THE PRESENCE, IDENTITY, OR SEVERITY OF A DISEASE OR CONDITION

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation. 129.-. (canceled)30. A method of determining the presence , identity , and/or severity of a disease or condition in an individual , wherein the disease or condition is associated with abnormal glycan biosynthesis , degradation , or accumulation , the method comprising:(a) generating a biomarker comprising of one or more non-reducing end glycan residual compound(s), wherein the biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme(s), wherein prior to enzyme treatment, the biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition;(b) detecting the presence of and/or measuring the amount of the biomarker produced using an analytical instrument and displaying or recording the presence of or the measure of the biomarker produced; and(c) correlating the presence of and/or the measure of the amount of the biomarker with the presence, identity, and/or severity of the disease or condition for determining the presence, identity, and/or severity of the disease or condition in the individual,wherein the disease or condition is a neurological disorder.31. The method of claim 30 , wherein the neurological disorder is Alzheimer's claim 30 , amyotrophic lateral sclerosis claim 30 , schizophrenia claim 30 , bipolar disorder claim 30 , depression claim 30 , epilepsy claim 30 , multiple sclerosis claim 30 , Parkinson's claim 30 , or stroke.32. The method of claim 30 , wherein the digesting glycan enzyme is selected from sialidase claim 30 , alpha 2 claim 30 ,8 sialidase claim 30 , alpha 2 claim 30 ,6 sialidase claim 30 , hexosaaminidase claim 30 , galactodidase claim 30 , fucosidase claim 30 , sulfatase claim 30 , alpha 2 ...

Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130-. (canceled)31. A method of determining in an individual the presence , identity , and/or severity of an MPS III disorder , the method comprising:(a) generating a biomarker comprising one or more saturated non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of heparan sulfate oligosaccharides, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS III disorder relative to individuals without the MPS III disorder; and(b) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence of and/or measure of the amounts of the biomarker are utilized to determine the presence, identity, and/or severity of the MPS III disorder; and{'sub': m', 'n', '3', 'p, 'wherein the biomarker is of Formula II: [GlcN(Ac)-(IdoA/GlcA)-GlcN(Ac)](SOR), wherein (IdoA/GlcA) is IdoA or GlcA; m and n are each independently 0 or 1; p is 0, 1, 2, 3, 4, or 5; and R is hydrogen or a negative charge.'}32. The method of claim 31 , wherein the biomarker is of Formula V: [GlcNAc-IdoA-GlcN(Ac)](SOR) claim 31 , wherein n is 0-1 and p is 0 claim 31 , 1 claim 31 , 2 claim 31 , or 3; or Formula VI: [GlcNAc-GlcA-GlcN(Ac)](SOR) claim 31 , wherein n is 0-1 and p is 0 claim 31 , 1 claim 31 , or 2.33. The method of claim 32 , wherein the biomarker of Formula V is selected from a group consisting of GlcNAc-IdoA-GlcNAc claim 32 , GlcNAc-IdoA2S-GlcNAc claim 32 , GlcNAc-IdoA-GlcNS claim 32 , GlcNAc-IdoA2S-GlcNS ...

Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Quantification of non-reducing end glycan residual compounds

A method of determining in an individual the presence, identity and/or severity of a disease or condition associated with abnormal glycan biosynthesis, degradation, or accumulation comprises (a) generating a first biomarker comprising a glycan residual compound and generating a second biomarker comprising a glycan residual compound; (c) using an analytical instrument to detect the presence of and/or measure the amount of the first and second biomarker produced and displaying or recording the presence of or a measure of a population of the first and second biomarkers, and (d) monitoring and/or comparing the amounts of the first and second biomarkers in a biological sample. The presence of and/or measure of the amounts of the first and second biomarkers are utilized to determine the presence, identity, and/or severity of the disease or condition. The first biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme and prior to the enzyme treatment, the first biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition. The first biomarker is a non-reducing end glycan residual compound. The second biomarker is generated by treating a population of glycans, in or isolated from a biological sample from the individual, with at least one digesting glycan enzyme in the same or different digestion step as provided in step (a) and prior to the enzyme treatment, the second biomarker is not present in abundance in samples from individuals with the disease or condition relative to individuals without the disease or condition, and provided that 1) the second biomarker is a non-reducing end glycan residual compound different from the first biomarker, 2) the second biomarker is a reducing end glycan residual compound, 3) the second biomarker is an internal glycan residual compound, or 4) ...

Quantification of non-reducing end glycan residual compounds

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Quantification of non-reducing end glycan residual compounds

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Quantification of non-reducing end glycan residual compounds

Quantification of non-reducing end glycan residual compounds

Heparan sulfate inhibitors

Provided herein are heparan sulfate inhibitors, including modulators of heparan sulfate glycosylation, heparan sulfate sulfation, and/or heparan sulfate epimerization.

Detection of oligosaccharides

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

Ganglioside biosynthesis modulators

Provided herein are ganglioside synthesis inhibitors, including modulators of ganglioside glycosylation

DNA encoding human vanilloid receptor VR3

Cultivator.

Heparan sulfate inhibitors

Provided herein are heparan sulfate inhibitors, including modulators of heparan sulfate glycosylation, heparan sulfate sulfation, and/or heparan sulfate epimerization.

Dna encoding human vanilloid receptor vr3

DNA encoding human VR1 receptor has been cloned and characterized. The recombinant protein is capable of forming biologically active protein. The cDNA's have been expressed in recombinant host cells that produce active recombinant protein. The recombinant protein is also purified from the recombinant host cells. In addition, the recombinant host cells are utilized to establish a method for identifying modulators of the receptor activity, a nd receptor modulators are identified.

METHOD FOR DIAGNOSIS OF DISORDER MPS IIIB

Παρεχόμενες στο παρόν είναι μέθοδοι για ανίχνευση ολιγοσακχαριδίων σε ένα βιολογικό δείγμα. Σε ειδικές περιπτώσεις, το βιολογικό δείγμα παρέχεται από ένα άτομο που υποφέρει από μία διαταραχή που συνδυάζεται με μη κανονική συσσώρευση γλυκοζαμινογλυκάνης.

Detection of oligosaccharides

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

Quantification of non-reducing end glycan residual compounds

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Ganglioside biosynthesis modulators

Method for diagnosing mps iiib disorder

Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

Quantification of non-reducing end glycan residual compounds

Provided herein are methods of diagnosing or monitoring the treatment of abnormal glycan accumulation or a disorder associated with abnormal glycan accumulation.

QUANTIFICATION OF GLYCAN RESTRICTIONS WITH NON-REDUCING END

N-linked glycan biosynthesis modulators

Ganglioside biosynthesis modulators

Provided herein are ganglioside synthesis inhibitors, including modulators of ganglioside glycosylation

Heparan sulfate inhibitors

Provided herein are heparan sulfate inhibitors, including modulators of heparan sulfate glycosylation, heparan sulfate sulfation, and/or heparan sulfate epimerization.

İndirgen olmayan uçlu glikan kalıntı bileşiklerinin nicelleştirilmesi.

Burada, anormal glikan birikiminin veya anormal glikan birikimi ile ilişkili bir rahatsızlığın tedavisinin tanılanması veya takip edilmesine dair yöntemler sağlanmaktadır.

Shock-absorber.

Heparin from modified mst cells and methods of making and using

Provided herein are methods of producing heparin and heparan sulfate from modified cells, such as modified MST cells, and compositions comprising heparin and heparan sulfate isolated from modified cells.